bidridistrogene xeboparvovec
Nucleic acidexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 10, 2018 (NCT03652259)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK1ANTISENSE INHIBITOR
JAK1 antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650240 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06246513 | Phase 3 | Jan 15, 2024 | Sarepta Therapeutics |
| NCT05876780 | Phase 1 | Dec 19, 2022 | Sarepta Therapeutics |
| NCT03652259 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2018 | Myonexus Therapeutics, Ohio State University, Sarepta Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sarepta Therapeutics | For profit | 3 | 3 | 3 | 2018 |
| Myonexus Therapeutics | For profit | 1 | 0 | 1 | 2018 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1